Abstract
742 / 5000 Výsledky překladu The general consensus reached by world diabetology over the last decade says that, given the reality, it is certainly very beneficial to start pharmacotherapy as soon as possible after the diagnosis of type 2 diabetes mellitus (DM2). More than 50 years of clinical experience and the results of prospective studies rank metformin as the first-line pharmacotherapy.
We consider it proven that the risk of serious complications and mortality are correlated with the compensation of diabetes, and on the contrary, intensive and safe treatment (lowering of glycaemia) is followed by reducing the risk of all chronic complications and reducing mortality. In addition to its effective ability to lower glycaemia and its ability to reduce weight gain, metformin has been shown to reduce cardiovascular risk.